Filip Janku
Chief Medical OfficerMr. Filip Janku is Member of Scientific Advisory Board of Fore Biotherapeutics Inc. He has M.D. from Univerzita Karlova v Praze, Ph.D. from Univerzita Karlova v Praze. He serves as Chief Medical Officer at Monte Rosa Therapeutics, Inc. since June 2021. He served as an Assistant Professor in the Department of Investigational Cancer Therapeutics (Phase I Program) and Center Medical Director for MD Anderson’s Clinical and Translational Research Center at MD Anderson Cancer Center from February 2012 to May 2021. He had been Scientific Advisor at Tessa Therapeutics Pte Ltd. until 2021. He research focuses on proof-of-concept clinical trials that possess a pivotal correlative component especially those involving liquid biopsies, molecular profiling of cell-free DNA, the PI3K/AKT/mTOR pathway and therapeutic use of oncolytic bacteria. He served as a Member of Clinical Advisory Board at IFM Therapeutics, LLC. He served as a Member of Clinical Advisory Board at Cardiff Oncology, Inc. (formerly known as TrovaGene, Inc.) until 2021. He has been a Member of the Scientific Advisory Board at Deciphera Pharmaceuticals, Inc. since June 23, 2015. He received multiple awards for his research efforts, including Sidney Kimmel Scholar award, several ASCO Merit Awards as well as an American Association for Cancer Research Scholar-in-Training Award. He obtained his MD and PhD at the Charles University Prague. He served as Member of Advisory Board at Celcuity Inc., since February 2020.
Positions
- Company NameMonte Rosa Therapeutics, Inc.Stock CodeGLUEPositionChief Medical OfficerColleagues
- MWMarkus WarmuthPresident, CEO & Director
- ANAndrew Newman SchiffIndependent Chairman of the Board
- PNPhilip NicksonChief Business & Legal Officer
- MBMatthew BowenCorporate Controller & Principal Accounting Officer
- JCJennifer ChampouxChief Operating Officer
- KLKimberly Lynn BlackwellIndependent Director
- CEChristine E. SiuIndependent Director
- JSJan SkvarkaIndependent Director
